Difference between revisions of "Technical Confirmation Process"

From QIBA Wiki
Jump to navigation Jump to search
Line 35: Line 35:
 
*** If each site tests all organs/cases, test coverage is simplest; however, it is acceptable for sites to test subsets as long as everything gets covered.
 
*** If each site tests all organs/cases, test coverage is simplest; however, it is acceptable for sites to test subsets as long as everything gets covered.
  
* Prepare the documents ('''RSNA Staff/Technical Committee''')
+
* Prepare field test materials/documents ('''RSNA Staff/Technical Committee''')
 
** Cover Letter
 
** Cover Letter
 
*** Many times a meeting is arranged between members of the field test site and members of the Biomarker Committee to describe the purpose of the field test and answer any questions the site may have.
 
*** Many times a meeting is arranged between members of the field test site and members of the Biomarker Committee to describe the purpose of the field test and answer any questions the site may have.

Revision as of 22:56, 6 July 2021

The Technical Confirmation Stage confirms it is practical for sites to perform the technical requirements to conform to the Profile.

Users in the field (clinical oncologists, imaging scientists, pharma, CRO’s, imaging vendors, software providers, etc.) attempt to conform to the Profile and provide feedback on the practicality of the requirements (and the usability of the document).

Whereas the preceding Public Comment Stage collected feedback based on people reading the Profile document itself, this stage seeks feedback on how well it works in a pilot implementation. As such, comments are solicited specifically from those that have used it and only those that have used it.

Considerations:

  • Profile authors have written requirements they believe are within the range of current reasonable practice in clinical use.
  • Sites are asked to consider, as they generate the biomarker according to the Profile, whether they would find the requirements practical in routine work.
  • Sites do not need to commit to using the Profile for all routine work going forward (although it would certainly be positive feedback if they chose to).
  • Sites are strongly encouraged to try to meet all the requirements
  • If the site is not comfortable using the procedures for patient scans, they can scan a phantom and note in their feedback that they used a phantom, and what details of the procedure made them uncomfortable.
  • If sites are uncomfortable meeting certain requirements with patients, that would make it hard to deploy the Profile so the Biomarker Committee may need to consider revising that requirement or better explaining/justifying it for sites.
  • Try to follow all requirements, even if scanning a phantom.
  • E.g. if the Profile has required breathing instructions, giving them to the phantom may help a site realize that the wording is incompatible with their preferred practice, or the text is poorly written, etc.
  • If the site is unable to conform to any requirements, comments on the nature of their difficulty or their reason for not conforming are very helpful to the Biomarker Committee.


The following Procedures list what is done (by whom).

Planning & Recruitment

  • Identify sites/people that will participate in the field test (Field Test Leader)
    • At least 3 sites are needed to get reasonable confirmation of results
    • Often Committee members may have personal contacts they can explore
      • "External" sites should be recruited to bring "fresh eyes" to better assess the clarity of the profile and bring different assumptions about routine practice for this biomarker.
      • Sites where Biomarker Committee members work may be easier to recruit since there is an existing champion, but they should make a point of engaging other fresh eyes (techs, physicists, radiologists, etc) and possibly stepping back when it comes time to perform the actual field test.
      • It can be helpful to have a mix of large academic centers, large hospitals, and smaller hospitals or imaging centers.
      • International feedback is desirable due to variations in practice and language; and QIBA Profiles are intended to be internationally applicable.
        • <TODO: Add links to contacts for Europe, Japan, US, etc.>
      • Core Labs can be effective field testers since they have experience with a variety of site practices and measurement needs
    • It may also be useful to call for volunteer sites on the QIBA mailing lists (RSNA Staff)
    • If a profile covers multiple organs/cases, the goal is to test all of them.
      • If each site tests all organs/cases, test coverage is simplest; however, it is acceptable for sites to test subsets as long as everything gets covered.
  • Prepare field test materials/documents (RSNA Staff/Technical Committee)
    • Cover Letter
      • Many times a meeting is arranged between members of the field test site and members of the Biomarker Committee to describe the purpose of the field test and answer any questions the site may have.
        • Consider recording the questions/answers since they may point to useful clarifications in the Profile
        • If a meeting is not possible, the information may be conveyed in a Cover Letter.
    • Site Details
    • Profile Requirements
      • Generally, the Profile Checklists are the core document.
      • The full Profile should also be made available as some sites will find it useful to have the context provided in the Overview and the explanations/clarifications in the Discussion sections.
    • Feedback Forms
      • One effective approach is to add two columns to the conformance checklists, to indicate for each requirement whether the site conformed to the requirement, and whether they found the requirement practical for routine use.
      • Additional General comments can be collected on a form similar to Public Comment.

Collecting Feedback

  • <Send materials to the site with instructions>
  • Email completed Feedback Template to Field Test leader (Commenters)
  • Collate all Feedback comments into a Feedback Resolution spreadsheet (RSNA Staff/Field Test Leader)
    • <Currently some flexibility is allowed in the form of the document. Process Cmte is working on a more tuned template>
    • Document test coverage: were all requirements tested. If coverage is incomplete <including organ coverage>, consider dropping the requirement or document the rationale for finding it technically confirmed in the absence of testing. <some sites may have done less than scheduled/intended><might not have needed coils on hand><BC notes lack of coverage and rationale for how to proceed><are there substantive practical issues, if not OK for Stage 3. Are there substantive performance issues, comes up in Stage 4>
  • Additionally, summarize feedback into a report (Field Test Leader).
  • Review comments, making changes to the document as needed (Technical Committee)
  • Record comment resolutions in spreadsheet
  • Vote on next step for the document (Technical Committee), either: <clarify with new wording>
    • refer the document to the Modality Committee for Technically Confirmed publication
    • conduct another round of field test on revised document
    • place the document into inactive status
  • Post Feedback Resolution spreadsheet, revised document to the Wiki (Field Test Leader/RSNA Staff)
  • If profile requirements didn't change significantly, test sites may be able to claim conformance.


(Cmte can decide if the full procedure has been "adequately" tested). Sites not doing requirement X is key feedback.

  • (Doing clinical patients exposes nuances,
  • <Committee may be faced with a response where none of the sites were comfortable executing the profile on patients and responded based on reading. In this case, the committee has done two public comments and no technical confirmation and has sites saying they are not comfortable with the profile. Should the committee advance the profile in this case? That would be pretty negative feedback>
  • <Profiles are generally written not to be unusual procedures><NOTE Didn't conform isn't a killer, it's the information we are trying to get. Might be better procedures, or might be superfluous>
  • <"Not routine, but can" also useful feedback - can do it but we really have to make the case for the value>


<When the TC 2020 version comes out, and a site tried the Consensus 2020 but only missed one requirement. Then the BC relaxed that requirement in the TC2020 (or 2021 explain ) draft, it would be nice if there was "change tracking" so they could see that now they would pass. Could have a "change tracked" document between each draft (but just the preceding, not all the combos, you have to step through the changes of history) Practically, we can point them to the newest, and maybe provide one "generation" of change track>

Feedback after Publication

The purpose of this process step is to actively seek and periodically respond to feedback on use of published documents. It is important to put this into context with other activities that may seem similar at first: Whereas the review and public comment steps that are part of the Drafting phase focus on the document itself, prior to its use, and the Collect Feedback step as part of the Field Test phase collects feedback on the initial use of the document given that it has been placed into trial implementation, this step is where longer-term, extended use of the document allows for actual assessment of its performance in practice. That is, over the course of time clinical trials may complete that had been designed with this, and/or other results from field usage may become evident either with the user or supplier base. As such, comments are solicited periodically for a wide range of the public that may connect with it in some way.

  • Periodically, collect list of people that may have used the document and/or professional societies that may have a particular relationship to the document (RSNA Staff)
  • Finalize comment form that will be used in the survey (RSNA Staff/Technical Committee)
  • Send announcement to mailing lists (RSNA Staff)
  • Email comments to RSNA Staff (Commenters)
    • commenters include full range of users of the document, e.g., vendors/suppliers, clinical oncologists, imaging scientists, pharma, CRO’s, etc. However, only people who have used document are included.
    • please use the provided comment form
  • Collate all comments into a spreadsheet (RSNA Staff)
    • Summarize range of feedback to the questions into a report for review by the technical committee provided by RSNA Staff.
    • Technical Committee decides what changes to make (if any) to the document and whether to refer it to the Modality Committee for re-publication of an updated version, whether to branch the document leaving the current version in place but spawning a derivative, or to retire the document
  • Record resolution in spreadsheet
    • Regardless of recommended status for this document, ensure that the results are made available to related activities